AlloVir (NASDAQ:ALVR) Shares Down 2.3% – Should You Sell?

AlloVir, Inc. (NASDAQ:ALVR)’s share price traded down 2.3% during mid-day trading on Friday . The stock traded as low as $2.50 and last traded at $2.50. 35,701 shares changed hands during mid-day trading, an increase of 133% from the average session volume of 15,312 shares. The stock had previously closed at $2.56.

AlloVir Trading Down 2.3%

The company has a market capitalization of $12.61 million, a PE ratio of -0.12 and a beta of 0.63. The firm’s 50-day simple moving average is $3.45 and its 200-day simple moving average is $7.27.

Institutional Investors Weigh In On AlloVir

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new stake in shares of AlloVir in the 4th quarter valued at about $31,000. Jane Street Group LLC raised its holdings in shares of AlloVir by 47.8% in the 4th quarter. Jane Street Group LLC now owns 123,159 shares of the company’s stock valued at $52,000 after purchasing an additional 39,808 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of AlloVir in the 4th quarter valued at about $142,000. Gilead Sciences Inc. bought a new stake in shares of AlloVir in the 4th quarter valued at about $6,987,000. Finally, Tang Capital Management LLC bought a new stake in shares of AlloVir in the 4th quarter valued at about $232,000. Institutional investors own 66.05% of the company’s stock.

AlloVir Company Profile

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.